Epidemiological Registry Describing Treatment Reality and Therapy Modalities of Patients With Malignant Lymphatic Systemic Diseases (Non-Hodgkin`s Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma) Requiring Therapy.
N/A
18 Years
N/A
18 Years
N/A
Open (Enrolling)
Both
Malignant Lymphatic Diseases
Both
Malignant Lymphatic Diseases
Trial Information
Epidemiological Registry Describing Treatment Reality and Therapy Modalities of Patients With Malignant Lymphatic Systemic Diseases (Non-Hodgkin`s Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma) Requiring Therapy.
Inclusion Criteria:
- Confirmed diagnosis of Non-Hodgkin`s lymphoma, chronic lymphocytic leukaemia or
multiple myeloma
- Must receive a first- or second-line therapy
- 18 years or older
- Signed, written informed consent
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Documentation of anamnestic data and therapy sequences
Outcome Time Frame:
5 years per patient
Safety Issue:
No
Authority:
Germany: Ethics Commission
Study ID:
IOM-TLN
NCT ID:
NCT00889798
Start Date:
April 2009
Completion Date:
October 2017
Related Keywords:
- Malignant Lymphatic Diseases
- Malignant lymphatic disease
- therapy-reality
- observation
- registry
- therapy sequences
- NHL
- CLL
- Germany
- lenalidomide
- alemtuzumab
- rituximab
- bendamustin
- thalidomide
- bortezomib
- ibritumomab-tiuxetan
- G-CSF
- chronic lymphocytic leukaemia
- follicular lymphoma
- gastric MALT lymphoma
- nongastric MALT lymphoma
- nodal marginal zone lymphoma
- splenic marginal zone lymphoma
- mantle cell lymphoma
- diffuse large b-cell lymphoma
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Lymphatic Diseases
Name | Location |
|---|
